Great Lakes NeuroTech (GLNT) has announced plans to collaborate with the pharmaceutical company UCB to provide individuals with Parkinson’s Disease (PD) and their clinicians with improved quantitative tools for assessing the impact of their current treatment with the aim of providing better individual patient experiences and, ultimately, improving quality of life.Parkinson’s causes motor symptoms of tremor, slowed movements, and impaired mobility, with side effects of medication including
Read More